natgillin/translations-raw huggingface dataset:
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets EU/1/09/596/001 20 tablets (blister) EU/1/09/596/002 30 tablets (blister) EU/1/09/596/003 60 tablets (blister) EU/1/09/596/004 90 tablets (blister) EU/1/09/596/005 100 tablets (blister) EU/1/09/596/006 500 tablets (blister) EU/1/09/596/007 60 tablets (bottle) EU/1/09/596/015 80 tablets (blister)
150 mg filmom obložene tablete EU/1/09/596/001 20 tableta (blister) EU/1/09/596/002 30 tableta (blister) EU/1/09/596/003 60 tableta (blister) EU/1/09/596/004 90 tableta (blister) EU/1/09/596/005 100 tableta (blister) EU/1/09/596/006 500 tableta (blister) EU/1/09/596/007 60 tableta (boca) EU/1/09/596/015 80 tableta (blister)
General disorders and administration site conditions Common: Fatigue, malaise, fever.
Opći poremećaji i reakcije na mjestu primjene Često: umor, slabost, vrućica
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure (CART).
naročito u bolesnika s uznapredovalom HIV bolešću i/ili dugotrajnom izloženošću kombiniranom antiretrovirusnom liječenju.
150 mg once daily
150 mg 100 mg jedanput na dan
The active ingredient in Lamivudine Teva Pharma B.V. is lamivudine.
Djelatna tvar u lijeku Lamivudin Teva Pharma B.V. je lamivudin.
In vitro data tend to suggest that the continuation of lamivudine in anti-retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness).
unatoč razvoju M184V, može osigurati rezidualnu antiretrovirusnu aktivnost (najvjerojatnije putem smanjene virulentnosti).
As well as the side effects listed below for Lamivudine Teva Pharma B.V., other conditions can develop during combination therapy for HIV.
Uz nuspojave lijeka Lamivudin Teva Pharma B.V. spomenute u daljnjem tekstu mogu se razviti i druga stanja tijekom primjene kombinirane terapije za HIV.
Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea.
Poremećaji probavnog sustava Često: mučnina, povraćanje, bol ili grčevi u abdomenu, proljev
The observed half-life of elimination is 5 to 7 hours.
U ispitivanjima je dokazano da je pri intravenoznoj primjeni srednji volumen raspodjele 1,3 l/kg i da je srednji poluživot eliminacije 5 -7 sati.
Nervous system disorders Common: Headache, insomnia.
Često: glavobolja, nesanica.
NAME OF THE MARKETING AUTHORISATION HOLDER TEVA B.V.
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET TEVA B.V.
These may affect up to 1 in 10,000 people:
Vrlo rijetke nuspojave Mogu se javiti kod najviše 1 od 10 000 ljudi:
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets: 60 ml container of 30 film-coated tablets.
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete: spremnik od 60 ml s 30 filmom obloženih tableta.
How to take Lamivudine Teva Pharma B.V.
Kako uzimati Lamivudin Teva Pharma B.V.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Rizik od nastupa ozbiljnih i potencijalno fatalnih jetrenih nuspojava povećan je u bolesnika koji su kronični nositelji virusa hepatitisa B ili C i koji su na kombinacijskoj antiretrovirusnoj terapiji.
Musculoskeletal and connective tissue disorders Common: Arthralgia, muscle disorders.
Često: artralgija, mišićni poremećaji
If you get any symptoms of infection while you are taking Lamivudine Teva Pharma B.V.: Tell your doctor immediately.
Ako zadobijete bilo koji od simptoma infekcije prilikom uzimanja lijeka Lamivudin Teva Pharma B.V.:
What Lamivudine Teva Pharma B.V. contains
Lamivudine Teva Pharma B.V. sadrži natrij
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight-band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
ispitivanje ARROW (COL105677) bilo je uključeno 1206 pedijatrijskih bolesnika u dobi od 3 mjeseca do 17 godina, kojima su se lijekovi dozirali sukladno preporukama za doziranje prema tjelesnoj težini,
• being sick (vomiting)
• mučnina • povraćanje
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Each film-coated tablet contains 300 mg lamivudine.
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 300 mg lamivudina.
2 to 12 years (N=19) PENTA 15 3 to 36 months (N=17)
3-36 mjeseci (N=17)
This may be administered as either 75 mg (one-half of a 150 mg tablet) taken in the morning and 150 mg (one whole 150 mg tablet) taken in the evening, or 225 mg (one and a half 150 mg tablets) taken once daily.
Može se primijeniti kao 75 mg (pola tablete od 150 mg) ujutro i 150 mg (jedna cijela tableta od 150 mg) navečer ili kao 225 mg (jedna i pol tableta od 150 mg) jedanput na dan.
The study demonstrated that foetuses exposed in utero to the combination sustained a higher level of nucleoside analogueDNA incorporation into multiple foetal organs, and showed evidence of more telomere shortening than in those exposed to zidovudine alone.
inkorporacije analoga nukleozida u više različitih fetalnih organa nego oni izloženi samo zidovudinu.
Administration of lamivudine tablets is bioequivalent to lamivudine oral solution with respect to AUC∞ and Cmax in adults.
Primjena Lamivudin tableta bioekvivalentna je Lamivudin oralnoj otopini s obzirom na
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets lamivudine
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete lamivudin
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Light grey, diamond shaped, biconvex film-coated tablet with approx. 14.5 mm length and 7.0 mm width - engraved with “L 150” and breakline on one side and breakline on the other.
Svijetlo siva, bikonveksna filmom obložena tableta u obliku dijamanta, oko 14,5 mm duga i 7,0 mm široka, s utisnutom oznakom “L 150” i razdjelnim urezom na jednoj strani te razdjelnim urezom na drugoj strani.
White opaque PVC/PVdC - Aluminium blisters Pack sizes of 20, 30, 60, 80, 90, 100 or 500 film-coated tablets
Veličina pakiranja: 20, 30, 60, 80, 90, 100 ili 500 filmom obloženih tableta
There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).
Također postoje uzvješća o disfunkciji mitohondrija u djece izložene nukleozidnim analozima in utero i/ili postnatalno
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A.
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A. Tel/Tél: +32 38207373
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account.
HIV infekcije u trudnica, a time i za smanjenje rizika od vertikalnog prijenosa HIV-a na novorođenče,
Dosing according to weight bands is recommended for Lamivudine Teva Pharma B.V. tablets.
Preporučuje se dozirati Lamivudin Teva Pharma B.V. tablete prema tjelesnoj težini.
How to store Lamivudine Teva Pharma B.V.
Kako čuvati Lamivudin Teva Pharma B.V.
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
alkohola, tešku imunosupresiju, visoki indeks tjelesne mase), opisani su slučajevi osteonekroze,
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets
150 mg filmom obložene tablete Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
Paediatric population: In a study performed in paediatric patients (see section 5.1 ARROW study), lower rates of virologic suppression and more frequent viral resistance were reported in children receiving an oral solution of lamivudine as compared to those receiving the tablet formulation.
ispitivanje ARROW), prijavljene su niže stope virusne supresije i češća rezistencija virusa u djece koja su primala oralnu otopinu lamivudina u usporedbi s djecom koja su primala tablete.
150 mg twice daily
150 mg dvaput na dan 150 mg 150 mg jedanput na dan
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON - LAMIVUDINE TEVA PHARMA B.V. 150 MG FILM-COATED TABLETS
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - LAMIVUDIN TEVA PHARMA B.V. 150 MG FILMOM OBLOŽENE TABLETE
• muscle pain and discomfort
Poremećaji metabolizma i prehrane
To ensure the administration of the entire dose, the tablet(s) should ideally be swallowed without crushing.
Tabletu se preporučuje uzeti cijelu (ne drobiti) kako bi se osigurao unos pune doze.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Each film-coated tablet contains 150 mg lamivudine.
150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 150 mg lamivudina.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg of lamivudine.
Jedna filmom obložena tableta sadrži 300 mg lamivudina
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON - LAMIVUDINE TEVA PHARMA B.V. 300 MG FILM-COATED TABLETS
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - LAMIVUDIN TEVA PHARMA B.V. 300 MG FILMOM OBLOŽENE TABLETE
Children weighing at least 14 kg and less than 20 kg The usual dose of Lamivudine Teva Pharma B.V. is 150 mg a day.
Za liječenje djece od navršena 3 mjeseca i tjelesne težine manje od 25 kg dostupna je i Lamivudin Teva Pharma B.V. tableta od 150 mg.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 150 mg of lamivudine.
Jedna filmom obložena tableta sadrži 150 mg lamivudina
With this condition, parts of the bone tissue die because of reduced blood supply to the bone.
Možete imati probleme s kostima Kod nekih se ljudi koji uzimaju kombiniranu terapiju za HIV javlja osteonekroza, bolest u kojoj dijelovi koštanog tkiva odumiru zbog smanjenog dotoka krvi u kost.
NAME OF THE MEDICINAL PRODUCT Lamivudine Teva Pharma B.V. 300 mg film-coated tablets lamivudine
Uputa o lijeku: Informacije za korisnika Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete lamivudin
Respiratory, thoracic and mediastinal disorders Common: Cough, nasal symptoms.
Često: kašalj, nazalni simptomi.
Uncommon: Transient elevations in liver enzymes (AST, ALT).
Manje često: prolazni porast jetrenih enzima (AST, ALT) Rijetko: hepatitis
When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Lamivudine Teva Pharma B.V. or other medicines you are taking, or an effect of the HIV disease itself.
Teva Pharma B.V. ili drugih lijekova koje uzimate ili se radi o simptomu same bolesti.
Some people taking Lamivudine Teva Pharma B.V. or other combination treatments for HIV are more at risk of serious side effects.
Rizik od pojave ozbiljnih nuspojava povećan je u nekih ljudi koji uzimaju Lamivudin Teva Pharma B.V. ili neku drugu kombiniranu terapiju za HIV.
Each film-coated tablet contains 300 mg. - The other ingredients are:
Jedna filmom obložena tableta sadrži 300 mg.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Lamivudine Teva Pharma B.V. 300mg film-coated tablets
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU Spremnik za tablete - Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
• if they have been taking combination therapy for a long time
Ta će se bolest prije javiti kod ljudi: • koji duže vrijeme uzimaju kombiniranu terapiju
This can be given as 75 mg (half a 150 mg tablet) in the morning and 150 mg (one whole 150 mg tablet) in the evening, or 225 mg (one and a half 150 mg tablets) once a day as advised by your doctor.
Može se primijeniti kao 75 mg (pola tablete od 150 mg) ujutro i 150 mg (jedna cijela tableta od 150 mg) navečer ili kao
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets: 50 ml container of 60 film-coated tablets.
150 mg filmom obložene tablete: spremnik od 50 ml s 60 filmom obloženih tableta.
Grey, diamond shaped, biconvex film-coated tablet - engraved with “L 300” on one side and plain on the other
Kako Lamivudin Teva Pharma B.V. izgleda i sadržaj pakiranja Siva, bikonveksna, filmom obložena tableta u obliku dijamanta, s utisnutom oznakom „L 300“ na jednoj strani i bez oznake na drugoj strani
Light grey, diamond shaped, biconvex film-coated tablet - engraved with “L 150” and breakline on one side and breakline on the other.
Kako Lamivudin Teva Pharma B.V. izgleda i sadržaj pakiranja Svijetlo siva, bikonveksna filmom obložena tableta u obliku dijamanta, s utisnutom oznakom „L 150“ i razdjelnom crtom na jednoj strani te razdjelnom crtom na drugoj strani.
This can be given as 75 mg (half a 150 mg tablet) twice a day (leaving approximately 12 hours between each dose), or 150 mg (one 150 mg tablet) once a day as advised by your doctor.
Može se primijeniti kao 75 mg (pola tablete od 150 mg) dvaput na dan (s razmakom od približno 12 sati između doza) ili kao
Skin and subcutaneous tissue disorders Common: Rash, alopecia.
Često: osip, alopecija Rijetko: angioedem
Adults, adolescents and children (weighing at least 25 kg) The recommended dose of lamivudine is 300 mg daily.
Preporuke za doziranje u odraslih, adolescenata i djece (težine najmanje 25 kg): Klirens kreatinina (ml/min)
If you take more Lamivudine Teva Pharma B.V. than you should Accidentally taking too much Lamivudine Teva Pharma B.V. is unlikely to cause any serious problems.
Ako uzmete više lijeka Lamivudin Teva Pharma B.V. nego što ste trebali
Each film-coated tablet contains 150 mg. - The other ingredients are:
Jedna filmom obložena tableta sadrži 150 mg.
Each infusion lasts 10 or 30 minutes, according to the dose.
Svaka infuzija traje 10 ili 30 minuta, ovisno o dozi.
It is given in four-week treatment cycles, on days 1, 2, 8, 9, 15 and 16 of each cycle.
Primjenjuje se u terapijskim ciklusima u trajanju od četiri tjedna, 1., 2., 8., 9., 15. i 16. dana svakog ciklusa.
It is given to adults who have received at least one previous treatment for their cancer.
Primjenjuje se u odraslih bolesnika koji su prethodno primili najmanje jednu terapiju protiv raka.
After the first week the dose is increased if the side effects are manageable.
Nakon prvog tjedna doza se povećava ako se nuspojave mogu kontrolirati.
Kyprolis (carfilzomib)
Kyprolis (karfilzomib)
What measures are being taken to ensure the safe and effective use of Kyprolis?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kyprolis?
Other information about Kyprolis
Ostale informacije o lijeku Kyprolis
This means that it blocks the proteasome, which is a system within the cells that breaks down proteins that are no longer needed.
To znači da djeluje blokiranjem proteazoma, odnosno sustava unutar stanice koji razgrađuje bjelančevine koje više nisu potrebne.
Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Ovdje možete pronaći dodatne informacije o uvrštenju lijekova za rijetke bolesti: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Cancer cells have an increased need to produce and break down proteins because they multiply rapidly.
Stanice raka imaju povećanu potrebu za stvaranjem i razgradnjom bjelančevina zbog toga što se brzo umnožavaju.
Kyprolis received a marketing authorisation valid throughout the EU on 19 November 2015.
Lijek Kyprolis je dobio odobrenje za stavljanje lijeka u promet koje je na snazi u Europskoj uniji od 19. studenoga 2015.
The most serious side effects include toxic effects on the heart, lungs and liver, and hypertension (high blood pressure) that can be severe.
Najozbiljnije nuspojave uključuju toksičnost za srce, jetru i pluća te hipertenziju (visok krvni tlak), koja može biti ozbiljna.
What is Kyprolis and what is it used for?
Što je Kyprolis i za što se koristi?
The Agency noted the unmet medical need for patients with multiple myeloma who no longer improve with the available therapies.
Agencija je istaknula postojanje nezadovoljene medicinske potrebe u bolesnika s multiplim mijelomom čije se stanje više ne poboljšava primjenom dostupnih oblika liječenja.
Side effects reported with Kyprolis are carefully evaluated and any necessary action taken to protect patients.
Nuspojave prijavljene za lijek Kyprolis pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
As for all medicines, data on the use of Kyprolis is continuously monitored.
Kao za sve lijekove, podatci o primjeni lijeka Kyprolis kontinuirano se prate.
Kyprolis is available as a powder to be made up into a solution for infusion (drip) into a vein.
Kyprolis je dostupan kao prašak za pripremu otopine za infuziju (drip) u venu.
The European Medicines Agency decided that Kyprolis' benefits are greater than its risks and it can be authorised for use in the EU.
Europska agencija za lijekove zaključila je da koristi lijeka Kyprolis nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
Why is Kyprolis authorised in the EU?
Zašto je lijek Kyprolis odobren u EU-u?
From cycle 13 onwards, the doses on day 8 and 9 are omitted if Kyprolis is used with lenalidomide and dexamethasone.
Od 13. ciklusa nadalje doze se ne daju 8. i 9. dana ako se Kyprolis primjenjuje s lenalidomidom i deksametazonom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kyprolis have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Kyprolis nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Other serious side effects are dyspnoea, acute kidney injury, tumour lysis syndrome (a complication due to the breakdown of cancer cells), infusion-related reactions, thrombocytopenia, internal bleeding, posterior reversible encephalopathy syndrome (a brain disorder that can cause headache, confusion, fits and loss of vision, and which may improve over time) as well as thrombotic microangiopathy and TTP/HUS (diseases involving problems with the blood clotting system).
Ostale su ozbiljne nuspojave dispneja, akutna ozljeda bubrega, sindrom lize tumora (komplikacija do koje dolazi kada se stanice raka raspadnu), reakcije povezane s infuzijom, trombocitopenija, unutarnje krvarenje, sindrom posteriorne reverzibilne encefalopatije (poremećaj mozga koji može prouzročiti glavobolju, zbunjenost, napadaje i gubitak vida, a može se poboljšati s vremenom) te trombotička mikroangiopatija i TTP/HUS (bolesti koje uključuju probleme sa zgrušavanjem krvi).
An overview of Kyprolis and why it is authorised in the EU
Pregled informacija o lijeku Kyprolis i zašto je odobren u EU-u
Regarding safety, although side effects, including severe effects, were seen with treatment involving Kyprolis, these were considered acceptable and manageable.
Što se tiče sigurnosti, premda su tijekom terapije lijekom Kyprolis uočene nuspojave, uključujući i ozbiljne nuspojave, smatra se da su prihvatljive i da se mogu kontrolirati.
Kyprolis must not be used in women who are breastfeeding.
Kyprolis se ne smije primjenjivati u trudnica ni dojilja.
When carfilzomib stops the proteasome from breaking down proteins in the cancer cells, the proteins build up and cause the cells to die, slowing down the growth of the cancer.
Kada karfilzomib spriječi proteazom u razgradnji bjelančevina u stanicama raka, bjelančevine se nakupljaju, što prouzročuje smrt stanica raka i usporavanje njegova rasta.
What are the risks associated with Kyprolis?
Koji su rizici povezani s lijekom Kyprolis?
Multiple myeloma is rare, and Kyprolis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 3 June 2008.
S obzirom na to da je multipli mijelom rijedak, Kyprolis se označava kao lijek za liječenje rijetkih bolesti od 3. lipnja 2008.
For more information about using Kyprolis, see the package leaflet or contact your doctor or pharmacist.
Više informacija o primjeni lijeka Kyprolis pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
Treatment may need to be stopped or the dose reduced, if the disease gets worse or the patient has severe side effects.
Ako se bolest pogorša ili se jave ozbiljne nuspojave, možda će biti potrebno prekinuti liječenje ili smanjiti dozu.
The most common side effects with Kyprolis (which may affect more than 1 in 5 people) are anaemia (low red blood cell counts), tiredness, nausea, diarrhoea, thrombocytopenia (low blood platelet counts), fever, dyspnoea (difficulty breathing), respiratory tract (airways) infection, cough and neutropenia (low levels of neutrophils, a type of white blood cell).
Najčešće nuspojave lijeka Kyprolis (koje se mogu javiti u više od 1 na 5 osoba) jesu anemija (niska razina crvenih krvnih stanica), umor, mučnina, proljev, trombocitopenija (niska razina trombocita), vrućica, dispneja (otežano disanje), infekcije dišnog sustava, kašalj i neutropenija (niske razine neutrofila, vrste bijelih krvnih stanica).
Kyprolis is a cancer medicine used together with the medicines lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow).
Kyprolis je citostatik koji se koristi zajedno s lijekovima lenalidomid i deksametazon ili samo s deksametazonom za liječenje multiplog mijeloma (raka koštane srži).
Further information on Kyprolis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Više informacija o lijeku Kyprolis možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reportsOvaj pregled informacija posljednji je put ažuriran u 03. 2018.
The active substance in Kyprolis, carfilzomib, is a proteasome inhibitor.
Djelatna tvar u lijeku Kyprolis, karfilzomib, inhibitor je proteazoma.
How does Kyprolis work?
Kako djeluje Kyprolis?
Kyprolis taken together with lenalidomide and dexamethasone has been compared with lenalidomide plus dexamethasone in one main study involving 792 patients with multiple myeloma whose disease had got worse after previous treatment.
Primjena lijeka Kyprolis s lenalidomidom i deksametazonom uspoređena je s primjenom lenalidomida i deksametazona u jednom glavnom ispitivanju koje je obuhvatilo 792 bolesnika s multiplim mijelomom čije se stanje pogoršalo nakon prethodne terapije.
Kyprolis contains the active substance carfilzomib.
Kyprolis sadržava djelatnu tvar karfilzomib.
What benefits of Kyprolis have been shown in studies?
Koje su koristi lijeka Kyprolis dokazane u ispitivanjima?
Kyprolis can only be obtained with a prescription and treatment must be supervised by a doctor experienced in the treatment of cancer.
Kyprolis se izdaje samo na liječnički recept te liječenje mora nadzirati liječnik s iskustvom u primjeni antitumorske terapije.
The study showed that Kyprolis is effective at prolonging the time patients lived without their disease getting worse (progression-free survival): patients receiving Kyprolis with lenalidomide and dexamethasone lived on average for 26.3 months without their disease getting worse, compared with 17.6 months for patients receiving lenalidomide plus dexamethasone.
Ispitivanje je pokazalo da je Kyprolis učinkovit u poboljšanju preživljenja bez ponovnog pogoršanja bolesti (stopa preživljenja bez progresije bolesti): bolesnici koji su uzimali Kyprolis uz lenalidomid i deksametazon u prosjeku su živjeli 26,3 mjeseca bez pogoršanja bolesti, u usporedbi sa 17,6 mjeseci u bolesnika koji su primali lenalidomid i deksametazon.